Phase I. Action Research
July 1, 2018 – June 30, 2019
Further development of the existing web app betaversion 01 into a final web app version, which can be used by finally millions of users at the same time
Phase II (in parallel)
July 1, 2018 – June 30, 2019
The development of mobile apps for ‘Diabetes Care Type 1’, ‘Diabetes Care Type 2’ ‘Cardio Care’ and Cardio Prevention‘ (all patients).
Omegon is the first ‘Crypto Company’, which brings a parallel bonus system to the market.
The bonus system is developed by our partner SMO Network AG and is part of the patented system ‘Individualized Health Management’ by Dr. Martin Mueller-Wolf and 4 research teams from his network.
From July 1, 2018 onwards, we contracted SMO Network AG and received 4 Web App Instruments and additionally the complete technology for the 4 first complete online systems ‘IndiBelt Diabetes Type 1’ (genetic), ‘IndiBelt Diabetes Type 2’ (lifestyle diabetes), ‘IndiBelt Cardiovascular’ (hypertension & cholesterol patients) and ‘IndiBelt Cardiovascular Prevention’ (for all other).
The bonus system consists of the promoters, the primary users and the secondary users.
The Individualized Diabetes Management-System ‘InDiMa’ is supporting the patient in a very personal way to cope with his health problems.
A comprehensive, empirically based questionnaire is provided, compriming all aspects that have been discussed in the scientific publication: Bio-Medical, Psychological, Personal and Socio-Systemic.
To bring all of these dimensions is unique and a ‘breakthrough’.
Questions are provided which are related to 10 factors which describe the current status of the patient. The current status in terms of the product definition is characterized in that certain mental, social, and psychological conditions of the patient are described that have influence on his/her coping with diabetes.
We are proud to introduce Omegon InDiMa:
the combination between the blockchain and Health Care apps
100% transparency for every buyer and token holder, proven by billions of Ethereum Blockchain users.
Suitable for many health insurances and governments: Omegon InDiMa improves the Health Care quality and reduces costs
Using the OMGN ERC20 tokens as an in-app payment currency guarantees immediate transactions and payments in every part of the world, for everyone.
OMEGON token is created on the basis of the Ethereum platform, the ETHASH algorithm, ERC20 token. The token abbreviation is OMGN and it has 18 decimal places.
24.12.2017 (00:00 CET)
2`000`000`000 OMGN (100%)
31.12.2018 (00:00 CET)
1 OMGN ERC20 Token = EUR 0.15
ETH, BTC, EUR
1 EUR or predefined packages
With help from our teams, contributors and investors these are the milestones we are looking forward to achieve.
Creation of the Whitepaper and the OMGN ERC20 Token
Sending the Whitepaper to FINMA, the Swiss Finance Market Authority for approvement
OMEGON AG becomes member of the Crypto Valley Association
Starting SmartContract Phase1: Early Bird
Team building, looking for developers, sales and investors
Token Pre-Sale until 30.04.2018
Start of the Web App Development
First closed tests with diabetes type I & II patients
Reaching ITO Goal of 500`000 EUR
Introducing the InDiMa OMEGON App in a first country with a roadshow. Goal: solid experience from real patients
Start of the mobile app development; Android first, then IOS. (Android has 86% market share)
End of Token Sale; all Tokens that are not sold will be destroyed.
Start of Global Exchange: the OMGN ERC20 token becomes available and tradable on crypto exchanges
Introducing the Web Apps and the Mobile Apps, extending their functionality.
Start of using the token for in-app payment with a first closed group of test users
The Humanization of Medical Applications
Many large IT companies have recognized this global trend and now invest significant time and money in the development of new applications that communicate directly with patients and treating physicians.
Thus, in the future, contact between patients (especially younger patients) and physicians will be reduced to a minimum, but all of the steps necessary to ensure treatment of the disease will be taken.
The ITO Crypto Team combines a passion for sports, cryptocurrencies & proven record in finance, development, health care, marketing & IT.
CSO: Chief Scientific Officer
Dr. Martin Mueller-Wolf is the Chief Scientific Officer.
He is the inventor and patent holder of the first worldwide ‘Individualized Health Management System’. This is the psycho-medical support system for the major eight chronic diseases, the standard ‘normal patient’, and for disabled persons. As entrepreneur and CEO of the SIP Group (SMO Network AG, InDiMa Intellectual Property AG and Personalized Health Care Holding AG) he is responsible for creating a value for our ‘Omegon Value Coin’.
Development Supervisor & Community Management
Darko brings over 20 years of experience and expertise in the community services, strategic planing, project design and implementation.
He worked with UNWFP, UNHCR and Danish Refugee Council in his humanitarian career and managed numerous EU and UN funded projects related to humanitarian crises and economy empowerment of local communities in Serbia, working closely with central and local institutions.
Darko recognised the potential of the OMEGON AG project and made a career decision to join our endavour.
Founded in 2014, Natura Sana is a Serbia-headquartered provider of IT consulting services and custom software development with 20+ IT professionals located internationally and locally.
For over 5 years we’ve been bringing custom and platform-based solutions to large and midsize companies in Healthcare, Banking, Retail, Telecom and other industries along with other influences rely on our solutions in their daily operations. With the background rooted in science, we build on our legacy knowledge and grow it in the areas of CRM, Data Analysis, Collaboration & Knowledge Management and Information Security.
Below we’ve provided a bit of ITO, ITO Token, cryptocurrencies, and few others. If you have any other questions, please get in touch using the contact form below.
ITO is an abbreviation for “Initial Token Offering”. ITO is a new method to raise funds. In comparison with standard venture capital, any individual or company can take part in ITOs.
A token is a digital asset that ICOs issue. When investing in ICOs, you get tokens that offer the potential to earn profits. Tokens can serve as a surrogate for cash, title of ownership or any other asset.
A White Paper is a technical document, which is drawn in a free format by the ICO team. Generally, this document offers a complete description for the project: its concept and advantages as compared to similar projects, team and roadmap.
An exchange is a system (website or application), where you can buy and sell any cryptocurrency (token) for another one at the current prices. The prices move based on supply and demand, shown by traders.
Unfortunately, US taxpayers are not allowed to participate in the token sale.
We have no guidelines and every project supporter should consider his own financial circumstances.
You will find a shop on our website shop.omegon.org, which you can use to buy OMEGON Tokens using cryptocurrencies. Our shop allows purchases with Bitcoin and Ethereum. Alternatively, payment can also be made in Euros.
The OMEGON Token will be used to pay for the functions of applications for "Individual Diabetes Management" and related applications.
In the ITO phase, from September 2018, all necessary steps will be taken to be fully prepared for placement. An exact date has not yet been set, but will be communicated in good time. OMEGON AG is positive that the placement will take place in the first quarter of 2019.
Our goal is the realization and market launch of the applications. The greater the success during token sales, the faster and more comprehensive the application can be developed and distributed. Development of a useful minimum version is possible with a six-figure sum. The subsequent developments must then be funded through the economic success of the application and are dependent on it.
OMEGON AG has its own token shop - to be found on shop.omegon.org. A detailed description and instruction videos can also be found on our website.
OMEGON AG, as the holding company, will be responsible for financing, central development management and organization. Among other things, the diabetes app, which is currently under development, will be part of this, for which it might be necessary to set up separate companies to take over marketing and region-specific further development.
On our website ito.omegon.org and in the whitepaper you will find various general details - for specific questions, please contact OMEGON AG directly via e-mail. You will find the contact details on our website.
InDiMa is an abbreviation of Individualized Diabetes Management. In general, it describes health-related applications that focus on the individual and person-specific treatment of one's own health. Additionally, to technical aids, communication, and self-management, the social environment network plays an important role.
1. An easy to use, self-explanatory system through information, questions, individual reports and individual action plans.
2. Complete systemic approach, i.e. consideration of biomedical markers, psycho-markers, perso-markers and socio-systemic-markers, which as a whole give a comprehensive picture of the person and make appropriate support possible.
3. Action- and solution-oriented: The application can show the user simply and understandably, where there is need for action in order to achieve better results. The user can see a clear distinction between urgent, imperative and optimizing need for action.
4. Efficient support for patient and physician: The physician remains in his central role. However, with the application, patient and physician have a tool that makes interaction much more efficient and increases the chances of treatment.
5. Complete picture thanks to the 360° report: The perspectives of patient and doctor are expanded to include the family and peer groups (self-help and therapy groups). The results become more meaningful, the patient's insights are enhanced and the will for self-improvement is increased.
6. Improvement of results and cost reduction through individualized joint approach: The user is accompanied by the application in three phases: (1) encouragement and empowerment, (2) collaboration and monitoring of goals, and (3) lifestyle management and adaptation. The following "roles" are involved, as required, in a person-centered manner: Analyzer, Supporter, Motivator and Realizer.